Group One Trading
BCYC

Group One Trading’s Bicycle Therapeutics BCYC Stock Holding History

Group One Trading’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,294
Closed -$9.77K – 8403
2025
Q2 		$8.99K Buy
1,294
+1,128
+680% +$8.98K ﹤0.01% 6786
2025
Q1 		$1.41K Sell
166
-300
-64% -$3.54K ﹤0.01% 7100
2024
Q4 		$6.52K Buy
+466
New +$9.99K ﹤0.01% 6306
2024
Q2 		– Sell
-91
Closed -$2.06K – 6718
2024
Q1 		$2.27K Sell
91
-26,173
-100% -$556K ﹤0.01% 6457
2023
Q4 		$475K Sell
26,264
-54,962
-68% -$909K ﹤0.01% 3121
2023
Q3 		$1.63M Sell
81,226
-2,741
-3% -$62.7K 0.01% 1820
2023
Q2 		$2.14M Buy
83,967
+35,528
+73% +$825K 0.01% 1657
2023
Q1 		$1.03M Buy
48,439
+9,655
+25% +$242K ﹤0.01% 2118
2022
Q4 		$1.15M Buy
+38,784
New +$1.04M ﹤0.01% 2293

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Group One Trading's BCYC Position: Q3 2025 in Review

Group One Trading sold out of Bicycle Therapeutics (BCYC) in Q3 2025, closing a stake of 1,294 shares — an estimated $9.77K sold.

Group One Trading first reported a position in BCYC in Q4 2022 and held it in 9 quarters. The position peaked at $2.14M in Q2 2023. 99 funds tracked by Wall St. Rank hold BCYC as of Q3 2025.

  • Group One Trading reported no remaining Bicycle Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Group One Trading sold 1,294 Bicycle Therapeutics shares in Q3 2025, an estimated $9.77K.
  • Group One Trading first reported a position in Bicycle Therapeutics in Q4 2022 and held it in 9 quarters.
  • Group One Trading's Bicycle Therapeutics position peaked at $2.14M in Q2 2023.
  • 99 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2025.

Based on Group One Trading's 13F filing for Q3 2025, filed 12 Nov 2025.